CF PharmTech published its first standalone Environmental, Social and Governance (ESG) report, covering the financial year ended 31 December 2025. The document combines operating data with detailed sustainability metrics.
Financial highlights • 2025 revenue reached RMB 432.52 million, compared with RMB 607.75 million a year earlier. • Net profit attributable to shareholders turned positive at RMB 2.49 million versus a RMB 21.09 million loss in 2024. • Total assets increased to RMB 1.78 billion, up 40.97 % year-on-year. • R&D expenditure amounted to RMB 124.55 million, representing 28.80 % of core business revenue; R&D personnel accounted for 30.85 % of total headcount.
Operational and product milestones • Six products are now commercialised, including Chang Qi® Budesonide Suspension and Shu Fei Min® Azelastine / Fluticasone Nasal Spray. • Arformoterol Tartrate Solution gained US FDA approval in May 2024 and completed its first overseas shipment in 2025. • The pipeline exceeds 20 candidates; two innovative inhaled therapies (IC004 for idiopathic pulmonary fibrosis and IC001 for pulmonary arterial hypertension) submitted IND applications during the year.
ESG governance • A three-tier structure—Board of Directors, ESG Working Group and functional departments—oversees sustainability strategy. • Independent directors hold one-third of board seats; all directors and 100 % of employees completed annual anti-corruption training, with no corruption cases reported.
Environment • Total greenhouse-gas emissions were 12,936.82 tCO₂e (Scope 1: 81.08 tCO₂e; Scope 2: 12,855.74 tCO₂e), equal to 0.30 tCO₂e per RMB 10,000 revenue. • Energy consumption totalled 3,256.97 tce, or 7.53 tce per million RMB revenue; an ISO 50001-certified management system is in place. • The company achieved zero discharge of production wastewater through on-site recycling. • Hazardous and non-hazardous waste compliant-disposal rates stood at 100 %.
Social • Total workforce was 610, with female employees representing 55 %. • Labour-contract coverage, social-insurance coverage and wage-payment coverage all reached 100 %. • No work-related fatalities occurred; the lost-time injury rate was 0.07. • Average training hours per employee rose to 61.38 and training coverage reached 100 %.
Supply chain • 87 qualified suppliers were engaged, 18 of which were overseas. • All new suppliers underwent ESG screening; no significant environmental or social violations were identified.
Community investment • Philanthropic donations totalled RMB 4.73 million, directed mainly toward education, poverty relief and medical assistance.
Outlook Management plans to maintain a dual-drive strategy of high-end complex formulations and innovative drugs while deepening carbon-reduction, water-saving and waste-minimisation targets in line with forthcoming science-based objectives.